TABLE 1

Patient Clinical and Pathologic Characteristics

Patient no.Primary siteAge (y)SexGradeMetastaticKi-67 (%) (primary tumor histology)Biomarker (pmol/L)Previous treatment
CgACgB
1Small bowel53F2Liver, bone>101,567170Surgery/RFA/177Lu*/octreotide
2Small bowel73F1Paraaortic lymph nodes, left SCF<1962558Surgery
3Lung56F2Bone<55071,328Octreotide
4Small bowel60F1Liver<214373Surgery/RFA/177Lu
5Lung68F2Mediastinal lymph nodes, bone174758Surgery/RFA/177Lu
6Pancreas70M2None570174Surgery
7Pancreas53F2Liver, bone995243Surgery/chemotherapy
8Lung41M2Lung, liver1224126Surgery/RFA/177Lu
9Pancreas†35M2None<549124Surgery

  • ↵* 177Lu-DOTATATE (peptide receptor radionuclide therapy).

  • ↵† MEN1.

  • RFA = radiofrequency ablation; SCF = supraclavicular fossa lymph node.